Phase 2 trial of BI 1482694 (HM61713), third-generation TKI, in T790M-positive NSCLC

Giorgio Scagliotti

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses a phase 2 trial of the efficacy and safety of BI 1482694 (HM61713), a third-generation epidermal growth factor receptor (EGFR) mutant-specific tyrosine kinase inhibitor (TKI), for the treatment of patients with T790M-positive non-small cell lung cancer (NSCLC).

Share this video